Literature DB >> 1891168

Relative importance of dose, body surface area, sex, and age for 5-fluorouracil clearance.

R E Port1, B Daniel, R W Ding, R Herrmann.   

Abstract

The pharmacokinetics of 5-fluorouracil (FU) has been investigated in 26 cancer patients; 15 of these patients were pretreated with methotrexate (MTX). FU was given by a constant rate intravenous infusion within 10 min, at doses of 320-960 mg/m2. Total plasma clearance, beta-half-life, and steady-state distribution volume were determined with 43 treatments, based on plasma level measurements up to 90 min after the end of the infusion. Average clearance decreased from 1.3 l/min for 320 to 0.7 l/min for 960 mg FU/m2. Multiple linear regression calculations with dose, body surface area, sex, age, and MTX pretreatment as independent variable and clearance as dependent variable confirmed the dependency of clearance on dose and body surface area but also showed that, with equal FU dose per m2, clearance was higher in males than in females, on the average, by 0.22 l/min. There was also suggestive (although not significant) evidence of a (reducing) influence of age on FU clearance.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1891168     DOI: 10.1159/000226942

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  22 in total

Review 1.  Pharmacology of anticancer drugs in the elderly population.

Authors:  Hans Wildiers; Martin S Highley; Ernst A de Bruijn; Allan T van Oosterom
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Patient profiling for treatment toxicity: potential use of clinical and genomic factors.

Authors:  Terri S Armstrong; Mark R Gilbert
Journal:  Curr Oncol Rep       Date:  2011-02       Impact factor: 5.075

Review 3.  Sex-specific aspects of tumor therapy.

Authors:  Kerstin Borgmann; Ekkehard Dikomey; Cordula Petersen; Petra Feyer; Ulrike Hoeller
Journal:  Radiat Environ Biophys       Date:  2009-02-26       Impact factor: 1.925

Review 4.  How important are gender differences in pharmacokinetics?

Authors:  Bernd Meibohm; Ingrid Beierle; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

5.  Pharmacokinetic analysis of sparse in vivo NMR spectroscopy data using relative parameters and the population approach.

Authors:  R E Port; H P Schlemmer; P Bachert
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 6.  Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer.

Authors:  F G Jansman; D T Sleijfer; J L Coenen; J C De Graaf; J R Brouwers
Journal:  Drug Saf       Date:  2000-10       Impact factor: 5.606

Review 7.  Can pharmacokinetic monitoring improve clinical use of fluorouracil?

Authors:  A M Young; S Daryanani; D J Kerr
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

Review 8.  Pharmacogenetics and pharmacogenomics of anticancer agents.

Authors:  R Stephanie Huang; Mark J Ratain
Journal:  CA Cancer J Clin       Date:  2009 Jan-Feb       Impact factor: 508.702

Review 9.  Gender differences in pharmacokinetics.

Authors:  C H Gleiter; U Gundert-Remy
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Apr-Jun       Impact factor: 2.441

Review 10.  Gender effects in pharmacokinetics and pharmacodynamics.

Authors:  R Z Harris; L Z Benet; J B Schwartz
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.